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Abstract. Background: Angiogenesis is a cellular process
that has been identified as a key target for therapy in solid
cancer. However, over the course of anti-angiogenic
therapies, cancer cells acquire resistance to these therapies
after an initial period of success. DME-25 is an extract
from Yang Zheng Xiao Ji, a traditional Chinese medicine
that has been reported to benefit patients with cancer by
alleviating chemotherapy-associated symptoms and
possibly inhibiting key cancer cell traits. This study aimed
to explore if DME-25 on its own and in combination with
avastin affected endothelial cell behaviour in vitro in the
presence of hypoxic lung cancer-conditioned medium (CM).
Materials and Methods: Two lung cancer cell lines, A549
and SK-MES-1, were exposed to hypoxic conditions (O2
≤1%) for 4 h, after which CM, and RNA were collected.
Transcript expression of several influential angiogenic
markers in lung cancer cells were assessed following
hypoxic/normoxic conditions. Lung cancer CM was added
in combination with avastin and DME-25, before or after
vascular endothelial growth factor (VEGF) depletion, to
endothelial cells (HECV) and cell migration and
microtubule formation were assessed in vitro. Results:
HECV cell migration was reduced in the presence of
avastin, although less efficiently in the presence of lung
cancer CM. A combination of DME-25 and avastin with
lung cancer CM significantly reduced HECV cell migration
irrespective of culture under hypoxia or normoxia.
Depletion of VEGF from the CM reduced the inhibitory
capacity of avastin, however, it appeared to have little
impact on the anti-angiogenic effects of DME-25.
Conclusion: DME-25 inhibits tubule formation
irrespectively of the factors secreted by normoxic or
hypoxic lung cancer cell CM depleted of VEGF.
Lung cancer is the most common cause of cancer-related
mortality in the UK accounting for more than one in five
deaths, a survival rate that has not improved since the 1970s
(1). One of the main reasons for this remains the late
diagnosis of the disease, which often leaves treatment
options limited, potentially even palliative, as illustrated by
the poor 5-year survival rate associated with lung cancer.
Anti-angiogenic therapies have demonstrated great promise,
particularly in lung cancer; however, due to acquired
resistance which develops, new treatments and targets
continue to be sought. 
Due to the advanced understanding of tumour biology,
the focus on identifying novel diagnostic, prognostic and
therapeutic molecular targets, especially with high
specificity for targeted processes, including angiogenesis,
has gained momentum. An essential protein that has been
identified in tumour angiogenesis is vascular endothelial
growth factor (VEGF), as well as its receptor signaling.
With the development and licensing of avastin
(bevacizumab), a monoclonal antibody against VEGF, the
promise of preventing tumour angiogenesis became
tangible (2). Avastin as a stand-alone treatment initially
yielded good results, however, it ultimately results in
tumour cells developing resistance. This resistance was
achieved by both cancer and normal cells re-balancing and
compensating with other pro-angiogenic mechanisms.
Therefore, avastin continues to be used in combination with
chemotherapy for advanced non-small cell lung cancer but
other ways of inhibiting tumour angiogenesis continue to
be sought.
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It has long been thought that hypoxia occurs within some
parts of malignant tissues, allowing a small subset of highly
aggressive tumour cells to adapt and survive in both
oxygen- and nutrient-deprived microenvironments. It has
been also demonstrated that an increase in genetic
instability and decrease in cell proliferation potentially
contribute to an increased capacity to metastasise in the
presence of hypoxia (3, 4). Often the use of VEGF-targeted
therapies, such as avastin, results in tumour hypoxia. Kim
et al. also demonstrated that the regulator of oxygen
homeostasis hypoxia-inducible factor 1α (HIF1α)
contributes to the development of resistance to avastin,
whilst Rapisarda et al. showed increased antitumour
activity achieved by combining avastin with HIF1α
inhibition (5, 6). Hypoxia-induced reactive oxygen species
have also been shown to alter endothelial cell genetic
profiles, potentially further enhancing the metastatic
potential of cancer cells (5, 7).
Complementary and alternative medicines and treatments
are gaining greater recognition throughout the Western
world as alternatives to standard therapies. In recent years,
several publications focusing on traditional Asian medicines
for cancer management have placed focus on these for
further scientific interest, resulting in several studies
attempting to elucidate their mechanisms of action. One
such combination of traditional Chinese herbs, Yangzheng
Xiao Ji (YZXJ), demonstrated an improvement in the
quality of life of patients with cancer through alleviation of
chemotherapeutic adverse effects (8). Subsequent
controlled clinical trials and meta-analyses have shown
benefits for patients with a broad range of cancer types,
including both lung and gastric cancer (9-12). Recent
exploration into the anticancer properties of YZXJ in vitro
by our group has shown inhibition of the adhesion and
migration of a range of cancer cells (13-15). YZXJ has also
been reported to benefit patients with lung cancer through
its ability to disrupt angiogenesis by interfering with
several common pathways utilised by endothelial cells.
These include inhibition of the focal adhesion kinase (FAK)
and RAC-alpha serine/threonine protein kinase (AKT)
pathways, as well as mitogen-induced cellular migration,
all of which are beyond the traditional angiogenic factor
activated pathways (e.g. the VEGF pathway), thus
potentially providing a method of overcoming acquired
resistance to current anti-angiogenic therapies (14, 16).
Materials and Methods
Cell lines. Lung cancer cell lines A549 and SK-MES-1 were
purchased from the American Type Culture Collection (Teddington,
Middlesex, UK) and the human vascular endothelial cell line HECV
was a kind gift from the National Institute for Cancer Research
(Genova, Italy). Lung cancer and endothelial cells were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% foetal calf serum (FCS) and antibiotic antimycotic
solution (containing penicillin, streptomycin and amphotericin B)
(Sigma Aldrich, Poole, Dorset, UK) and incubated at 37˚C, with 5%
CO2 and 95% humidity. For experiments, cells were washed twice
and subsequently incubated in DMEM supplemented with Serum
Replacement factor 1 (Sigma-Aldrich). Hypoxic conditions were
induced using an EVOS chamber (Life Technologies, Paisley, UK)
with oxygen levels set at 1%.
Treatment of cancer cells under hypoxia and normoxia. Avastin was
bought from University Hospital of Wales Pharmacy, reconstituted
in a 0.1% solution of bovine serum albumin/balanced saline solution
(BSA/BSS) and used for all experiments at a final concentration of
10 μg/ml.
DME-25, an extract of YZXJ capsules (Yiling Pharmaceutical,
Hebei, China) containing a combination of 16 herbs was prepared as
previously described (17). In brief, the herbal combination of YZXJ
was incubated with DMSO for 24 h at 4˚C. Insoluble constituents
were subsequently removed by centrifugation and the remaining
extract called DME-25. The DME-25 extract was used at a final
concentration of 1:1,000 for all experiments.
Lung cancer cells were treated under normoxia in a routinely
maintained incubator supplied with 5% CO2 and air. For hypoxia,
lung cells were placed in a special chamber linked to nitrogen, CO2
and oxygen, and was programmed to supply 1% oxygen for 4 h.
Cells were processed for RNA extraction at the end of the
incubation and prepared for quantitative gene-transcript analysis. 
Preparation of conditioned medium. Lung cancer cells were seeded
into duplicate individual 35×10 mm with vent cell culture dishes
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Table I. Primer sequences used in the quantitative gene transcript
analyses.
Target sequence Sequence (5’-3’) Predicted 
product 
size (bp)
GAPDH F CTGAGTACGTCGTGGAGTC 93
GAPDH ZR CAGAGATGATGATGACCCTTTTG
PDPN F GAATCATCGTTGTGGTTATG
PDPN ZR CTTTCATTTGCCTATCACAT
IL8 F TCTCTTGGCAGCCTTCCT 94
IL8 ZR TGTCTTTATGCACTGACATCT
VEGFA F GAGCCGGAGAGGGAG 127
VEGFA ZR CTGGGACCACTTGGCAT
VEGFC F CTACAGATGTGGGGGTTGCT 64
VEGFC ZR GTAGCTCGTGCTGGTGTTCA
VEGFD F CAGGGCTGCTTCTAGTTTGG 67
VEGFD ZR TCTCCACAGCTTCCAGTCCT
HIF1α F TTGGAGATGTTAGCTCCCTA 87
HIF1α ZR GGAACTGCTTTCTAATGGTG
HGF F TACGCTACGAAGTCTGTGAC 105
HGF ZR TCTTGCCTGATTCTGTATGA
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; PDPN:
podoplanin; IL8: Interleukin-8; VEGFA/B/C/D: Vascular endothelial
growth factor A/B/C/D; HIF1α: Hypoxic inducible factor 1 alpha; HGF:
Hepatocyte growth factor. ACTGAACCTGACCGTACA – ZR probe
sequence, attached to the 5’ end of each of the reverse primers.
(Greiner Bio-one, Stonehouse, Gloucestershire, UK) at a density of
7.5×105/ml and left to settle overnight. Cell monolayers were
washed twice in BSS and replaced with DMEM supplemented with
1.5ml of serum replacement factor 1. Dishes were placed either into
an incubator set at 37˚C, with 5% CO2 and 95% humidity
(considered to be normoxia) or in the EVOS chamber with oxygen
levels set at 1% for 4 h (hypoxia). Media was subsequently collected
and separated into two Eppendorfs for subsequent migration and
tubule formation assays.
RNA isolation, cDNA generation and quantitative PCR (qPCR).
RNA was isolated from cultured cells using the Trizol protocol as
stated by Sigma Aldrich. In brief, 1 ml of Tri reagent was added to
the monolayer of cells to induce lysis. Subsequently the supernatant
was transferred to a 1.5 ml Eppendorf containing 200 μl of
chloroform (Sigma-Aldrich). Samples were shaken and then
centrifuged at 12,000 × g for 15 min at 4˚C. The upper aqueous
phase was carefully removed and transferred to a new Eppendorf
tube containing 500 μl of isopropanol (Sigma-Aldrich). The samples
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Figure 1. Transcript expression of HIF-1α in lung cancer cells. A: In A549 lung cancer cells exposed to hypoxia for 4 hours HIF1α transcript
expression significantly increased compared to the normoxic control (*p=0.03). B: In SK-MES-1 lung cancer cells exposed to hypoxia for 4 hours
HIF1α transcript expression significantly increased compared to the normoxic control (*p=0.03).
Figure 2. Transcript expression of vascular endothelial growth factor (VEGFA), hepatocyte growth factor (HGF) and  interleukin 8 (IL8) in lung
cancer cells. A: In A549 lung cancer cells exposed to hypoxia for 4 h, VEGFA and HGF transcript expression decreased, although this did not reach
significance. IL8 transcript expression increased, although again not reaching significance. B: In SK-MES-1 lung cancer cells exposed to hypoxia
for 4 h, VEGF and HGF transcript expression was reduced, although not reaching significance. IL8 transcript expression was significantly reduced
(p=0.03) compared to the normoxic control. 
were shaken and then centrifuged at 12,000 × g for 10 min at 4˚C.
The supernatant was removed from the Eppendorf tube and replaced
with 1 ml 75% ethanol: diethyl pyrocarbonate (DEPC) water after
which it was centrifuged at 7,500 × g for 5 min. Ethanol:DEPC was
removed and the pellet left to air dry at room temperature for a few
minutes. The pellet was subsequently resuspended in DEPC water
prior to quantification.
RNA was quantified using an IMPLEN Nanophotometer
(Munchen, Germany) which was programmed to detect single-
stranded RNA (μg/μl) at 260:280 nm ratio using DEPC water as a
control. All RNA was standardised to 500 ng.
cDNA to screen for the genes listed in Table I was generated
using Precision nanoScript 2 Reverse Transcription kit (Primer
Design Southampton, UK). The quantitative analyses were carried
out using quantitative transcript analysis with Ampliflor™
technology, which uses a universal probe and a pair of gene-specific
primers (one of which carries an additional Z-sequence). qPCR was
carried out on a StepOne-Plus unit (ABI, Loughborough,
Leicestershire, UK) with a custom master mix from Primer Design.
An internal standard was included in each of the assays and used to
calculate the sample transcript levels. All PCR reactions, following
cDNA synthesis, were normalised to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). 
Supernatant VEGF depletion. The supernatant from lung cancer
cells was used to treat HECV cells with and without VEGF
depletion. VEGF depletion was achieved using immunoprecipitation
with neutralizing antibody to VEGF (ab9570; ABCAM, Cambridge,
Cambridgeshire, UK) as described below. Supernatant was divided
into two equal volumes (750 μl). One aliquot was incubated with
agarose beads coated in BSS, while the other aliquot was incubated
with agarose beads and anti-VEGF (Neutralisation density (ND50)
10 ng/ml) for 2 h at 4˚C rotating on a blood wheel. Agarose beads
were subsequently removed from the samples by centrifugation at
5000 × g for 5 min, after which the supernatants were transferred
to fresh Eppendorf tubes and labelled as VEGF-containing (control)
or VEGF-depleted samples.
Electric cell-substrate impedance sensing (ECIS) for analysing cell
adhesion and migration. Cell adhesion and migration were assessed
using the high-throughput ECIS method as previously reported (18).
ECIS was conducted using an ECIS-Theta model equipped with a
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Figure 3. Impact of avastin in the presence of medium from hypoxic lung cancer cells. A: Conditioned medium from normoxic A549 lung cancer cells
increased human vascular endothelial (HECV) cell migration, that was negated by the addition of avastin. B: Conditioned medium from hypoxic A549
lung cancer cells increased HECV cell migration, that was negated by the addition of avastin. C: The combination of hypoxic conditioned media and
avastin reduced HECV cell migration less than that observed under normoxic conditions. SRF: Serum replacement factor. 
wounding module and in the 96W1E cell arrays, both supplied by
Applied Biophysics (Troy, NJ, USA). In brief, 1×105 HECV cells
were seeded per well and treated with combinations of the
supernatant, both control and VEGF-depleted, avastin with/without
DME-25. Cells were monitored and the change in resistance over
time measured until levels plateaued. Subsequently, in order to
assess cell migration, a wound was created by passing an electrical
current through the gold electrodes, and cell migration was
determined using changes in resistance as cells migrated back over
the edges of the artificial wound. 
Microtubule-formation assay. A 96-well plate was pre-coated with
10 mg/ml of Matrigel (Corning, St. Davids Park, Flintshire, UK)
(~50 μl/well) and left to set at room temperature for approximately
30 min. Each well was seeded with 4×104 HECV cells resuspended
in DMEM supplemented with serum replacement factor and
appropriate treatment combinations of avastin and DME-25.
Results
Changes of angiogenic and other factors associated with
angiogenesis under normoxia and hypoxia in human lung
cancer cells. In both A549 and SK-MES-1 lung cancer cells
exposed to hypoxic conditions for 4 h, there was a
significant increase in HIF-1α transcript expression
compared to the respective normoxic control (p=0.01)
(Figure 1A and B, respectively). The other angiogenic
markers screened, VEGFA, hepatocyte growth factor (HGF)
and interleukin 8 (IL8) appeared to differ in their response
between cell lines. In A459 cells, VEGFA and HGF
transcript expression seemed to be reduced after 4 h of
hypoxia, whereas IL8 transcript expression increased,
however, none of these changes crossed the statistical
Owen et al: Effect of YZXJ on Endothelial Cells
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Figure 4. Impact of avastin and DME-25 in the presence of hypoxic lung cancer media. A) The combination of avastin and DME-25 with A549
normoxic conditioned media significantly reduced HECV cell migration. B) The combination of avastin and DME-25 with A549 hypoxic conditioned
media significantly reduced HECV cell migration. C) The combination of avastin and DME-25 with A549 4h normoxic conditioned media
significantly reduced HECV cell migration, compared to control and avastin alone. D) The combination of avastin and DME-25 with SK-MES-1 4h
normoxic conditioned media significantly reduced HECV cell migration, compared to control and avastin alone. SRF: Serum replacement factor.
threshold (p≤0.05) when compared to the normoxic control
(Figure 2A). However, in the SK-MES-1 lung cancer cells
exposed to hypoxia for 4 h VEGFA, HGF and IL8 transcript
expression was reduced (Figure 2B). Of these reductions,
IL8 was the only one to cross the significance threshold
(p=0.03). However, the reduction in VEGFA was close to
significance (p=0.06) when compared to the normoxic
control. Multiple other members of the VEGF family
transcript expressions (VEGF-C and -D) were screened.
After 4 h hypoxia when compared to the normoxic control;
no difference in expression patterns was observed between
these family members and VEGFA (Data not shown).
Evaluation of the response of HECV cells to conditioned
medium from lung cancer cells. When HECV cells were
treated with the serum replacement factor (SRF) medium
and compared to a supplemented medium control there
was no difference (Figure 3A). There was also no
difference in cell migration when the SRF medium was
added in addition to avastin (Figure 3A). When A549 lung
cancer-conditioned medium was added to HECV cells,
there was an increase in HECV cell migration, although
this did not reach statistical difference compared to the
serum replacement control (Figure 3A). As expected, the
conditioned medium from A549 lung cancer cells when
combined with avastin resulted in a significant decrease in
HECV cell migration (Figure 3A, p=0.01 vs. SRF control).
The addition of avastin to the A549 conditioned medium
appeared to restore the level of HECV cell migration to
that seen in the SRF control. A similar trend in HECV cell
migration was observed when cells were exposed to
conditioned medium from hypoxic A549 cells (Figure 3B),
although the effect of avastin appeared to be reduced, and
did not reach significance compared to the SRF control
ANTICANCER RESEARCH 36: 1181-1192 (2016)
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Figure 5. Impact of avastin and DME-25 in the presence of hypoxic lung cancer media after VEGF-depletion. A) The combination of avastin and
DME-25 with A549 normoxic conditioned media significantly reduced HECV cell migration compared to the VEGF-depleted. B) The combination
of avastin and DME-25 with A549 hypoxic conditioned media significantly reduced HECV cell migration. C) The combination of avastin and DME-
25 with A549 4hrs normoxic conditioned media significantly reduced HECV cell migration, compared to control and avastin alone. D) The
combination of avastin and DME-25 with SK-MES-1 4h hypoxic conditioned media significantly reduced HECV cell migration, compared to control
and avastin alone. SRF: Serum replacement factor.
(p=0.198). When conditioned medium from cells under
hypoxia and under normoxia were directly compared, there
was no difference in HECV cell migration (Figure 3C).
There was a reduction in HECV cell migration response
when avastin was added in combination with the respective
conditioned medium. The addition of avastin resulted in a
greater reduction in HECV migration when added to
conditioned medium from normoxic cells rather than
hypoxic ones (Figure 3C). 
When SRF medium was added to HECV cells in
combination with avastin and DME-25, HECV cell
migration was significantly reduced compared to avastin
and the serum replacement factor medium control (Figure
4A and B respectively, p<0.001 vs. control). A similar
reduction in HECV cell migration was also seen when
A549 normoxic (Figure 4C, p<0.001 vs. control) and
hypoxia (Figure 4D, p<0.001 vs. control) conditioned
medium was added. Under both conditions, the combined
addition of avastin and DME-25 resulted in significant
reductions in HECV cell migration (p<0.001). With
normoxic conditioned medium, this reduction reached
significance compared both to the normoxic control and
avastin standalone treatment (p=0.01). HECV cell
migration was also significantly reduced when compared to
the hypoxic control (p<0.001), however, this was not noted
when compared to the control with avastin alone.
Owen et al: Effect of YZXJ on Endothelial Cells
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Figure 6. Impact of avastin and DME-25 on HECV tubule formation in the presence of A549 lung cancer media. A) Micro-tubule formation was
reduced in HECV cells treated with A549 normoxic media in combination with avastin, DME-25 or a combination of DME-25 and avastin. B)
Micro-tubule formation was reduced in HECV cells treated with A549 4h normoxic media in combination with avastin, DME-25 or a combination
of DME-25 and avastin. C) VEGF-depletion of A549 normoxia media removed the inhibitory influence of avastin, however DME-25 and a
combination of DME-25 and avastin still inhibited micro-tubule formation. D) VEGF-depletion of A549 4h normoxia media removed the inhibitory
influence of avastin, however DME-25 and a combination of DME-25 and avastin still inhibited micro-tubule formation. E) Media control with
avastin, DME-25 or avastin and DME-25 all inhibited microtubule formation in HECV cells. SRF: Serum replacement factor, CM: conditioned
medium, VEGF: vascular endothelial growth factor.
The conditioned medium from A549 lung cancer cells
was also added to HECV cells after VEGF depletion
(Figure 5). As expected, when avastin was added to these
cells, less of an effect was noticed on HECV cell
migration, with both the hypoxic and normoxic samples
with avastin failing to cross the significance threshold
(p=0.121 and 0.771, respectively). This was particularly
noticeable under treatment with normoxic-conditioned
medium (Figure 5C). The addition of both avastin and
DME-25 in combination did significantly reduce HECV
cell migration compared to the VEGF-depleted controls in
both the normoxic and hypoxic conditioned medium (both
p<0.001) (Figure 5C and D). 
Tubule formation by HECV cells in response to conditioned
media from lung cancer cells. As has been previously
reported, the addition of avastin inhibits HECV microtubule
formation in vitro compared to a serum replacement factor
medium control. DME-25 extract also inhibited HECV
microtubule formation, both on its own and in combination
with avastin (Figure 6A). This pattern was mirrored in the
presence of A549 lung cancer cell-conditioned media
(Figure 6B). After VEGF depletion of the A549 cell-
conditioned media, the addition of avastin appeared to have
little impact on microtubule formation in vitro compared to
the controls (Figure 6C and D). Irrespective of VEGF
depletion, the addition of DME-25 in combination with
ANTICANCER RESEARCH 36: 1181-1192 (2016)
1188
Figure 7. Impact of avastin and DME-25 on HECV tubule formation in the presence of hypoxic A549 lung cancer media. A)  Micro-tubule formation
was reduced in HECV cells treated with A549 hypoxic media in combination with avastin, DME-25 or a combination of DME-25 and avastin. B)
Micro-tubule formation was unaffected in HECV cells treated with A549 4h hypoxic media and avastin. However, DME-25 or a combination of
avastin and DME-25 inhibited HECV tubule formation. C) VEGF-depletion of A549 hypoxic media removed the inhibitory influence of avastin,
however DME-25 and a combination of DME-25 and avastin still inhibited micro-tubule formation. D) VEGF-depletion of A549 4h hypoxic media
removed the inhibitory influence of avastin, however DME-25 and a combination of DME-25 and avastin still inhibited micro-tubule formation. E)
Media control with avastin, DME-25 or avastin and DME-25 all inhibited microtubule formation in HECV cells. SRF: Serum replacement factor, CM:
conditioned medium, VEGF: vascular endothelial growth factor.
A549 cell-conditioned media continued to inhibit HECV
cell tubule formation. However, the addition of a
combination of A549 VEGF-depleted conditioned media,
avastin and DME-25 did not lead to the same level of
inhibition as DME-25 on its own, microtubule formation
appeared to have returned to levels similar to those seen in
the control (Figure 6D). 
When HECV cells were exposed to avastin and SRF
medium tubule formation appeared to be inhibited (Figure
7A). Conditioned medium from A549 cells under hypoxic
conditions and avastin did not appear to inhibit tubule
formation (Figure 7B). The addition of DME-25 or avastin
and DME-25 in combination with conditioned medium from
A549 cells under hypoxic conditions did reduce HECV cell
microtubule formation (Figures 7A and B respectively). As
noted, under the normoxic conditioned medium (Figure 6D)
VEGF-depletion from hypoxic conditioned medium
prevented avastin from inhibiting microtubule formation
(Figure 7C and D respectively). However, unlike in normoxic
conditions the addition of DME-25 or a combination of
avastin and DME-25 appeared to continue inhibiting
microtubule formation under the influence of A549 hypoxic
conditioned medium. 
The SK-MES-1 normoxia conditioned medium appeared
to have little impact on microtubule formation in vitro
irrespective of VEGF-depletion or in the presence of avastin
Owen et al: Effect of YZXJ on Endothelial Cells
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Figure 8. Impact of avastin and DME-25 on HECV tubule formation in the presence of normoxic SK-MES-1 lung cancer media. A)  Micro-tubule
formation was reduced in HECV cells treated with SK-MES-1 noroxic media in combination with avastin, DME-25 or a combination of DME-25 and
avastin. B) Micro-tubule formation was reduced in HECV cells treated with SK-MES-1 4h noroxic media in combination with avastin, DME-25 or
a combination of DME-25 and avastin. C) VEGF-depletion of SK-MES-1 normoxia media did not remove the inhibitory influence of avastin, however
DME-25 appeared to have little impact on HECV micro-tubule formation.  A combination of DME-25 and avastin inhibited micro-tubule formation.
D) VEGF-depletion of SK-MES-1 4h normoxia media removed the inhibitory influence of avastin, however DME-25 and a combination of DME-25
and avastin still inhibited micro-tubule formation. E) Media control with DME-25 or avastin and DME-25 all inhibited microtubule formation in
HECV cells. SRF: Serum replacement factor, CM: conditioned medium, VEGF: vascular endothelial growth factor.
compared to the SRF medium control (Figure 8A –D). The
addition of DME-25 to the SK-MES-1 normoxia conditioned
medium reduced HECV microtubule formation despite
VEGF depletion (Figures 8B and D). This trend was also
mirrored when SK-MES-1 conditioned medium was added
in combination with avastin and DME-25. 
In the conditioned medium from hypoxic SK-MES-1 cells,
avastin inhibited microtubule formation compared to the SRF
controls (Figure 9A and B respectively). As was noted in the
normoxic conditions the addition of DME-25 also inhibited
microtubule formation. In the VEGF-depleted control SRF
HECV microtubule formation was unaffected by the presence
of avastin (Figure 9C). However, this trend was not maintained
in the SK-MES-1 hypoxic conditioned medium group. When
VEGF-depleted SK-MES-1 conditioned medium was added in
combination with avastin, HECV microtubule formation was
inhibited. VEGF-depletion did not appear to alter the inhibitory
effects that DME-25 or the combination of DME-25 and
avastin had on HECV microtubule formation in the presence
of SK-MES-1 conditioned media (Figure 9D).
Discussion 
With the limitations of avastin as a standalone anti-angiogenic
treatment now known, research is continuing in order to
identify new angiogenic factors that can be targeted in
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Figure 9. Impact of avastin and DME-25 on HECV tubule formation in the presence of hypoxic SK-MES-1 lung cancer media. A) Micro-tubule
formation was reduced in HECV cells treated with SK-MES-1 hypoxic media in combination with avastin, DME-25 or a combination of DME-25 and
avastin. B) Micro-tubule formation was reduced in HECV cells treated with SK-MES-1 4h hypoxic media in combination with avastin, DME-25 or
a combination of DME-25 and avastin. C) VEGF-depletion of SK-MES-1 hypoxic media removed the inhibitory influence of avastin, however DME-
25 or a combination of avastin and DME-25 still inhibited HECV micro-tubule formation. D) VEGF-depletion of SK-MES-1 4h hypoxia media
however did not remove the inhibitory influence of avastin, whilst DME-25 and a combination of DME-25 and avastin continued to inhibit micro-
tubule formation. E) Media control with DME-25 or avastin and DME-25 all inhibited microtubule formation in HECV cells. SRF: Serum
replacement factor, CM: conditioned medium, VEGF: vascular endothelial growth factor.
combination with VEGF. This approach has resulted in modern
medicine embracing some of the ancient traditional Asian
medicines, as demonstrated by the active ongoing research
investigating the use and mechanisms of action of YZXJ and
its extract DME-25. This study suggests that the combination
of DME-25 and avastin can affect vascular endothelial cell
behaviour (migration and microtubule formation) when
exposed to pro-angiogenic factors secreted by A549 and SK-
MES-1 cells in vitro. This study also demonstrated that factors
secreted under hypoxic conditions, particularly by SK-MES-1
cells, result in HECV cells responding less effectively to
avastin, although the combination of the YZXJ extract, DME-
25, with avastin negated this. 
Our group has previously the shown that YZXJ and its
extract DME-25 can influence migratory behaviour of HECV
cells and a variety of cancer cells in vitro through inhibition
of the tyrosine phosphorylation of FAK (17). FAK has since
long been linked with cell migration and angiogenesis (19).
Although the active component(s) of YZXJ remain unknown,
this small study demonstrates that it inhibits key pro-tubule
formation behaviour of endothelial cells on its own and in
the presence of avastin, in the presence of normoxic and
hypoxic conditioned media from lung cancer cells. Thus,
targeting of the FAK pathway may offer greater benefit in
targeting cells that are exposed to hypoxic conditions, not
only by inhibition of angiogenesis but also through reducing
the migratory potential of endothelial cells. FAK inhibitors
are already undergoing testing and have yielded some
promising results. The combination of FAK and proto-
oncogene tyrosine-protein kinase src inhibitors have
demonstrated increased antitumour activity against non-small
cell lung cancer (20), while in ovarian cancer, a combination
of FAK inhibitors and chemotherapy agents have
demonstrated promise in overcoming resistance (21, 22).
Herein, and in other previous studies, we showed that this
combination of herbs affects a diverse range of cancer cell
types and endothelial cell adhesive and migratory properties,
this may also provide additional benefits in cancer therapy
by limiting the metastatic potential of cells. Therefore, given
the potential of hypoxic conditions to drive genetic changes
in cancer cells that result in a more metastatic phenotype,
discovering and embracing therapeutics that could combat
this behaviour may provide novel outlooks in cancer
treatment.
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